These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23226035)

  • 1. Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine.
    Barone C; Mousa SS; Mousa SA
    Pharmgenomics Pers Med; 2009; 2():59-67. PubMed ID: 23226035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
    Yip VL; Pirmohamed M
    Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in thrombosis.
    Mousa SA
    Methods Mol Biol; 2010; 663():277-89. PubMed ID: 20617424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is personalized medicine a dream or a reality?
    Morse BL; Kim RB
    Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
    Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
    Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes.
    Muyambo S; Ndadza A; Soko ND; Kruger B; Kadzirange G; Chimusa E; Masimirembwa CM; Ntsekhe M; Nhachi CFB; Dandara C
    OMICS; 2022 Jan; 26(1):35-50. PubMed ID: 34958284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics in osteoporosis: Steps toward personalized medicine.
    Greene R; Mousa SS; Ardawi M; Qari M; Mousa SA
    Pharmgenomics Pers Med; 2009; 2():69-78. PubMed ID: 23226036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
    Visscher H; Amstutz U; Sistonen J; Ross CJ; Hayden MR; Carleton BC
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):228-39. PubMed ID: 21386709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current role of pharmacogenomics in cardiovascular medicine.
    Musunuru K
    Curr Treat Options Cardiovasc Med; 2011 Aug; 13(4):302-12. PubMed ID: 21537956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort.
    Mukherjee C; Sweet KM; Luzum JA; Abdel-Rasoul M; Christman MF; Kitzmiller JP
    Per Med; 2017 Sep; 14(5):383-388. PubMed ID: 29181084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.
    Berinstein E; Levy A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):973-983. PubMed ID: 28792790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.
    Bader LA; Elewa H
    PLoS One; 2016; 11(12):e0168732. PubMed ID: 27992547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.
    Ong FS; Deignan JL; Kuo JZ; Bernstein KE; Rotter JI; Grody WW; Das K
    Pharmacogenomics; 2012 Mar; 13(4):465-75. PubMed ID: 22380001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics steps toward personalized medicine.
    Xie HG; Frueh FW
    Per Med; 2005 Nov; 2(4):325-337. PubMed ID: 29788578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.
    French B; Joo J; Geller NL; Kimmel SE; Rosenberg Y; Anderson JL; Gage BF; Johnson JA; Ellenberg JH;
    Trials; 2010 Nov; 11():108. PubMed ID: 21083927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.